knowledge -WSS

knowledge

author：hotspot 2025-09-28 18:31:00 - browse：13539

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

hotspot

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

eGenesis tests gene

A revolution in caring for preterm infants

Research misconduct: Proposed new rules face resistance

Humana cuts profit projections as Medicare Advantage costs soar

Humana cuts profit projections as Medicare Advantage costs soar

hotspot

knowledge

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

What the Wegovy shortage looks like for doctors — and for patients

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Merck, J&J, and long Covid

Affirmative action in medical school literally saved lives

Dewpoint Therapeutics lays off staff after losing partnerships

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare Advantage today, explained in one chart

hotspot

Cancer cells are shown to suck energy source from immune cells

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

European regulators consider appeal over Amylyx ALS drug

AI generated plenty of interest at JPM but not a lot of trust

Female surgeons have lower rates of long

A fraught question for the kids of Alzheimer’s: Is it coming for us?

entertainment

hotspot

hotspot

hotspot